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Abstract. Fasudil, a Rho kinase (ROCK) inhibitor, effectively 
inhibits disease severity in a mouse model of Alzheimer's 
disease (AD). However, given its significant limitations, 
including a relatively narrow safety window and poor oral 
bioavailability, Fasudil is not suitable for long-term use. 
Thus, screening for ROCK inhibitor(s) that are more efficient, 
safer, can be used orally and suitable for long-term use in the 
treatment of neurodegenerative disorders is required. The main 
purpose of the present study is to explore whether FSD-C10, 
a novel ROCK inhibitor, has therapeutic potential in amyloid 
precursor protein/presenilin-1 transgenic (APP/PS1 Tg) mice, 
and to determine possible mechanisms of its action. The 
results showed that FSD-C10 effectively improved learning 
and memory impairment, accompanied by reduced expression 
of amyloid-β 1-42 (Aβ1-42), Tau protein phosphorylation (P-tau) 
and β-site APP-cleaving enzyme in the hippocampus and 
cortex area of brain. In addition, FSD-C10 administration 
boosted the expression of synapse-associated proteins, such 
as postynaptic density protein 95, synaptophsin, α-amino 
3-hydroxy-5-methyl-4-isoxa-zolep-propionate receptor and 
neurotrophic factors, e,g., brain-derived neurotrophic factor 
and glial cell line-derived neurotrophic factor. Taken together, 
our results demonstrate that FSD-C10 has therapeutic potential 
in the AD mouse model, possibly through inhibiting the 
formation of Aβ1-42 and P-tau, and promoting the generation of 
synapse-associated proteins and neurotrophic factors.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder 
that occurs mainly in old age; it is characterized by deposits 
of amyloid-β (Aβ) plaques and neurofibrillary tangles, and 
neuronal loss (1), and its prevalence is rapidly increasing. 
It is likely that AD has multiple etiologies, although its 
precise cause remains unknown (2). Aβ and tau proteins 
constitute a prime neurotoxic component of senile plaques 
in the brain of AD patients, thus contributing to learning 
and memory impairment due to synaptic dysfunction and 
neuronal degeneration (3). However, to date most therapeutic 
interventions aimed at modifying a single pathological factor 
(e.g., cholinergic dysfunction, or Aβ aberrant processing) have 
failed because they target only limited pathogenic factors 
of AD (4). Inflammation, mitochondrial dysfunction, and 
oxidative stress are considered the most prominent concomitant 
pathological events (5-7), being potential targets of therapeutic 
intervention. Recently, the ER-associated degradation (ERAD) 
pathway has also been drawing widespread attention as control 
of protein-folding intermediaries in AD (8,9).
Inflammation has been proposed as a main factor in the 
pathogenesis of AD, including microglial activation, reactive 
astrocytes and inflammatory molecules (2,10‑12). However, 
it has been noted that microglial activation exhibits both 
beneficial and detrimental effects depending on the stage of 
microglia (13). The conversion of microglia from detrimental 
(M1) to beneficial (M2) phenotype may contribute to an 
anti‑inflammatory microenvironment in the brain (14). Similar 
to microglia, astrocytes also contribute to neuroinflamma-
tion in AD by releasing inflammatory cytokines and other 
toxic molecules (15). The ubiquitin-proteasome system and 
autophagy mechanisms are impaired due to the toxic effects of 
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Aβ and oxidative stress damage, leading to the accumulation 
of oxidized/unfolded proteins that may contribute to neuronal 
loss (16). In fact, non-steroidal anti-inflammatory drugs 
(NSAIDS) initially garnered enthusiasm from pre-clinical 
and epidemiologic studies as agents for reducing the risk of 
AD (17), but anti‑inflammatory treatment failed to produce 
beneficial effects in patients with severe cognitive impairment 
and dementia (18).
It has been reported that Rho activity, which is thought to 
contribute to AD pathogenesis (19), was elevated in the brain 
of AD model mice (20). Pharmacologic inhibition of Rho 
kinase (ROCK) induced protein degradation by autophagy in 
mammalian cells (21), and suppressed Aβ production in an AD 
mouse model (22), highlighting ROCK as a therapeutic target 
to combat Aβ production in AD. Fasudil, a selective ROCK 
inhibitor, increased dendrite branching and stabilized dendrite 
arbors in CA1 pyramidal neurons of APP/PS1 mice (23) by 
preventing neurodegeneration and stimulating neuroregenera-
tion in various neurological disorders (19). Our previous study 
also confirmed that Fasudil treatment ameliorated memory 
deficits in APP/PS1 transgenic mice, accompanied by a 
decrease in Aβ deposits, p-Tau and BACE levels, an increase 
in PSD-95, and inhibition of the TLRS-NF-κB-MyD88 
inflammatory cytokine axis (24).
Although previous studies have demonstrated certain 
beneficial effects of Fasudil intervention in the AD model (24), 
several lines of evidence suggest that there are some limita-
tions in the clinical use of Fasudil, including its suitability only 
for short-course treatment, low oral bioavailability, a narrow 
safety window and blood pressure fluctuation. Thus, novel 
ROCK inhibitor(s) that are more efficient, safer, oral and suit-
able for long-term use for the treatment of neurodegenerative 
disorders are required. In the present study, we explored the 
therapeutic effect and systemic response of a novel ROCK 
inhibitor, FSD-C10, and possible mechanisms of its action in 
the treatment of a mouse model of AD.
Materials and methods
Animals and treatment. Experiments were performed on 
male APP/PS1 double transgenic mice (APPswe/PS1dE9, 
8-month-old), purchased from Shanghai Research Center. 
Age-matched wild-type (WT) mice were used as controls. 
All animals were housed in a room maintained at 25˚C with 
a 12-h light/dark cycle. The mice were given free access to 
food and water except during the behavioral test. The experi-
ment was carried out in compliance with the Guidelines for 
Animal Care and Use of China, and approved by the Animal 
Ethics Committee of Shanxi Datong University, Datong, 
China (Ethical Approval no. 1601). Every effort was made to 
minimize suffering of the animals.
The experimental design was carried out in two stages: 
Validation of the AD model and intervention of the AD model. 
For validation of the AD model, mice were divided into two 
groups: Age-matched wild-type (n=8) and APP/PS1 trans-
genic mice (n=8). Mice were sacrificed at 8 months of age. 
Behavioral and pathological changes were measured before 
and after execution. For the intervention of FSD-C10, mice 
were divided into two groups: Normal saline (NS)-control 
mice (n=8) and FSD-C10-treated mice (n=8). Mice were 
treated with FSD-C10 (25 mg/kg/day every other day) or NS 
(0.9% NaCl) for 2 months by intraperitoneal (i.p.) injection. 
The concentration of FSD-C10 used in this study was adopted 
based on our preliminary experiments.
Mouse spatial learning and memory test. Spatial learning 
and memory of mice were assessed using the Morris water 
maze (MWM) test. The MWM is a 90 cm high, 50 cm diam-
eter circular pool, containing a submerged escape platform 
(5.0x5.0 cm), 2.0 cm below the water surface. The pool was 
filled with water containing an edible white pigment that made 
the water opaque, and the water temperature was maintained 
at 23-25˚C. In each trial, the time required to escape onto the 
hidden platform was recorded as escape latency. Mice were 
allowed a maximum of 60 sec to reach the platform, and if 
they failed to do so, they were guided to the platform. After 
training was completed, cognitive function was measured for 
5 days, after which the platform was removed for spatial explo-
ration in order to determine the memory capacity of the mouse 
as to the platform space position. All behavioral parameters of 
mice were tracked, recorded and analyzed using SMART 3.0 
(Panlab, Barcelona, Spain).
Histopathology and immunohistochemistry. At the end of the 
final behavioral test, mice were anesthetized and transcardially 
perfused with NS and 4% paraformaldehyde in phosphate-buff-
ered saline (PBS). Brains were sliced (10 µm) and analyzed by 
immunohistochemistry. Briefly, slides were blocked with 1% 
BSA (Sigma) for 1 h, and permeated with 0.3% Triton X-100 in 
1% BSA/PBS for 30 min at RT. Sections were incubated with 
anti-Aβ1-42 (1:1,000; EMD Millipore, Billerica, MA, USA), 
anti-p-Tau (1:1,000; Cell Signaling Technology, Inc., Danvers, 
MA, USA), anti-BACE (1:1,00; Cell Signaling Technology, 
Inc.), anti-synaptophin (1:1,000), anti-AMPAR-1 (1:1,000), 
anti-AMPAR-2 (1:1,000; all from Abcam, Cambridge, MA, 
USA), anti-BDNF (1:1,000; Promega Corporation, Madison, 
WI, USA), and anti-GDNF (1:1,000; Promega Corporation) at 
4˚C overnight. After washing, the slices were incubated with 
secondary antibodies at RT for 2 h. The nucleus was stained 
by Hoechst 33342 (1 µg/ml, Sigma-Aldrich; Merck KGaA, 
Darmstadt, Germany). Control sections were run following 
identical protocols, but the primary antibodies were omitted. 
Results were visualized under fluorescence microscopy by 
IMAGE-PRO PLUS software (Media Cybernetics, Inc., 
Rockville, MD, USA). Quantification analysis of positive cells 
was performed on three sections per animal, and four mice per 
group were analyzed in a blinded fashion.
Western blot analysis. Proteins of mouse brain were extracted 
as previously described (17), Protein concentrations were 
determined by a bicinchoninic acid (BCA) kit (Beyotime 
Institute of Biotechnology, Haimen, China). Protein samples 
were separated by SDS-PAGE and transferred onto PVDF 
membranes. After nonspecific binding was blocked with 5% 
nonfat dry milk, membranes were incubated at 4˚C overnight 
with primary antibodies (Aβ1-42, p-Tau, BACE, PSD-95, 
AMPAR-1, AMPAR-2, BDNF, GDNF and β-actin). The next 
day, the membranes were washed three to four times with 
0.1% Tween-20/TBST (pH 7.6) and incubated with horse-
radish peroxidase-conjugated anti-rabbit IgG or anti-mouse 
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IgG secondary antibodies for 2 h at 37˚C. To compare protein 
loading, antibodies directed against GAPDH or β-actin were 
used and relative optical density was measured with Image Lab 
Software (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Statistical analysis. Graph Pad Prism 5 (Cabit Information 
Technology Co., Ltd., Shanghai, China) was used for statistical 
analysis. Results are presented as mean ± SEM. An unpaired, 
two-tailed Student's t-test was used for comparisons of means 
between two groups. In all tests, P<0.05 was considered to 
indicate a statistically significant difference.
Results
Behavioral and pathological changes in APP/PS1 mice 
at 8 months of age. To observe the effect of FSD-C10 in 
APP/PS1 transgenic mice, we first tested the behavioral and 
pathological changes at the initiation time of drug intervention 
as a baseline. Memory and learning ability was measured by 
MWM and the expression of Aβ1-42, p-Tau and BACE protein 
was determined by western blot. As shown in Fig. 1, APP/PS1 
transgenic mice exhibited obvious space learning and memory 
impairment at 8 months of age, as compared with the WT 
group. Simultaneously, the levels of Aβ1-42, p-Tau and BACE 
expression were more elevated in APP/PS1 transgenic mice 
than in the WT group (P<0.01, P<0.05 and P<0.05, respec-
tively; Fig. 1B). Together, APP/PS1 mice showed the typical 
behavior dysfunction and typical pathologic abnormality of 
AD, thus confirming the AD model in these transgenic mice.
FSD‑C10 improves learning and memory abilities of the 
APP/PS1 Tg mice. As shown in Fig. 1, APP/PS1 transgenic 
mice had obvious space learning and memory impairment at 
8 months of age compared with the WT group. To observe 
whether FSD‑C10 can ameliorate the deficit in learning and 
memory ability, MWM measurement was used in APP/PS1 
mice after 2 months of treatment (Fig. 2A and B). As shown 
in Fig. 2C, FSD‑C10 intervention significantly reduced the 
time and distance for Latency to Target (P<0.01), Latency 
1st Entrance to SW (P<0.05), and mean distances to Target 
(P<0.05) of these AD mice.
When the platform was moved, a consolidation of spatial 
memory was detected. The results showed that the movement of 
FSD-C10-treated mice mainly located on the position of the target 
platform quadrant, while NS-controlled mice mainly moved 
around the location of the target platform quadrant (Fig. 2A and B). 
The intervention of FSD-C10 increased Time in SW (P<0.01; 
Fig. 2C) and Distance in SW (P<0.05; Fig. 2C) as compared 
with the NS control group. However, there were no differences in 
global activity between two groups (P>0.05; Fig. 2C).
FSD‑C10 attenuates Aβ burden, Tau phosphorylation and 
BACE expression. We evaluated the pathological changes 
in APP/PS1 transgenic mice, including Aβ plaques, Tau 
phosphorylation and BACE expression by immunohistochem-
istry and western blot. As shown in Fig. 3A, the numbers of 
Aβ1-42-positive cells in the hippocampus and cortex of brain 
were lower in FSD-C10-treated mice than in NS-treated control 
mice. Similarly, FSD-C10 intervention suppressed Aβ1-42 
protein level in brain when compared with the NS-treated 
control group (P<0.01; Fig. 3B).
We further explored the levels of p-tau and BACE proteins 
in the hippocampus and cortex with immunohistochemistry 
and western blot. The results showed that the numbers of 
p‑Tau and BACE positive cells were significantly lower in 
FSD-C10-treated group than in the NS-treated control group 
Figure 1. AD transgenic mouse model. At 8 months of age, learning and memory ability was measured by the Morris Water Maze. (A) Compared with the 
WT group, APP/PS1 transgenic mice exhibited obvious space learning and memory impairment. (B) At the same time, expression of Aβ1-42, p-Tau and BACE 
protein was increased as measured by western blot. The results suggest that APP/PS1 mice showed typical behavior dysfunction and and typical pathologic 
abnormality of AD. Results are expressed as the fold change relative to β-actin as the loading control. Quantitative results are shown as mean ± SEM of 4 mice 
each group. *P<0.05 and **P<0.01 vs. Wild-type. AD, Alzheimer's disease.
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(P<0.05 and P<0.01 for p-Tau; P<0.05 and P<0.05 for BACE; 
Fig. 4A). Similarly, FSD-C10 treatment inhibited the expres-
sion of p-Tau and BACE protein in brain when compared 
with the NS-treated control mice (P<0.05; Fig. 4B). These 
results suggest that FSD-C10 treatment effectively alleviated 
pathological changes in AD mice.
FSD‑C10 induces the expression of synapse‑associated 
proteins. It has become clear that cognitive dysfunction more 
strongly correlates with synapse loss in AD than with counts of 
plaques, tangles, and neuronal loss (25,26). Our results showed 
that FSD-C10 treatment up-regulated synaptophsin expression 
in the hippocampus (P<0.01; Fig. 5A) as well as AMPAR-1 
and AMPAR-2 expression in the cortex (P<0.01 and P<0.05, 
respectively; Fig. 5A) as compared with NS-treated control 
mice. Data from western blot also confirmed that FSD‑C10 
treatment up-regulated the expression of AMPAR-1 and 
AMPAR-2 protein in brain (both P<0.01; Fig. 5B).
PSD-95 is a synaptic protein that regulates synaptic distri-
bution, synaptic stability and certain types of memory (27). 
As shown in Fig. 5B, FSD-C10 treatment elevated the level of 
PSD-95 expression in brain as compared with the NS-treated 
control group (P<0.05; Fig. 5B). These results indicate that the 
improvement in learning and memory impairment mediated 
by FSD-C10 may be related to the up-regulation of these 
synapse-associated proteins in both hippocampus and cortex.
FSD‑C10 increases the expression of neurotrophic factors. 
Neurotrophic factors are well known to be important for 
the survival, differentiation, growth and regeneration of 
neurons (28), as well as for synaptic transmission and plas-
ticity (29). In this research, we explored the role of FSD-C10 
in production of neurotrophic factors. Immunohistochemical 
analysis revealed that FSD-C10 intervention increased the 
numbers of both BDNF and GDNF positive cells in the hippo-
campus and cortex of brain compared with the NS-treated 
control group (P<0.01 and P<0.05 respectively; Fig. 6A). 
Expression of BDNF and GDNF protein was also higher in 
FSD-C10-treated mice than in the NS-treated control group 
measured by western blot (both P<0.05; Fig. 6B). FSD-C10 
thus has a potentially neuroprotective effect through the 
production of neurotrophic factors.
Discussion
AD is an age-related and chronic neurodegenerative disorder 
presenting as progressive cognitive decline. Although the exact 
pathogenesis is not yet clear, multiple etiologic pathways have 
Figure 2. FSD‑C10 improves behavioral deficits of APP/PS1 Tg mice. Cognitive ability was analyzed in a Morris water maze test. The Morris water maze test 
began two months after NS/FSD-C10 administration. (A) 8-zone Morris water maze schematic diagram, (B) typical diagram of two groups, and (C) Latency to 
Target, Latency 1st Entrance to SW, Mean Distances to Target, Time in SW (%), Distance in SW and Global Activity (%). Results are shown as mean ± SEM 
of 8 mice each group. *P<0.05 and **P<0.01 vs. APP/PS1+NS. 
EXPERIMENTAL AND THERAPEUTIC MEDICINE  16:  3929-3938,  2018 3933
been considered (2). The major histopathological hallmarks 
of AD include Aβ plaques and neurofibrillary tangles (NFTs) 
formed by hyperphosphorylated Tau protein (30), and the 
neurite atrophy and synaptic loss induced by Aβ are considered 
to be the major cause of gradual cognitive detetrioration in 
AD (31). Neurotoxicity of Aβ becomes apparent via induction 
of oxidative stress, neuronal excitotoxicity, neuroinflammation 
and apoptosis (32,33). One of the most promising strategies 
for treatment of AD is to directly target Aβ by decreasing the 
production and clearing aggregation of Aβ (34). In addition 
to Aβ accumulation, tau hyperphosphorylation is also an 
important pathological hallmark of AD (35). Abnormal phos-
phorylation of tau protein promotes the loss of microtubule 
stabilizing ability and may contribute to neurite degeneration 
as well as NFT formation (36). Current drugs for AD treatment, 
such as acetylcholinesterase inhibitor and NMDA antagonist, 
show limited benefits in most AD patients (37). There is thus 
an urgent need for novel therapeutic strategies that can halt the 
Figure 3. FSD-C10 attenuates Aβ1-42 burden in hippocampus and cortex in APP/PS1 Tg mice. Aβ1-42 was measured by immunohistochemistry and western 
blot on two months after FSD-C10 administration. (A) Aβ1-42 expression was measured in hippocampus and cortex by immunohistochemistry and (B) in brain 
tissue by western blot. Quantitative results are shown as mean ± SEM of 4 mice each group, and one representative of three independent experiments. *P<0.05 
and **P<0.01 vs. APP/PS1+NS.
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disease process and are suitable for long-term clinical manage-
ment. In our previous studies, a comparative study of Fasudil 
and FSD-C10 has been reported, including cell viability, cell 
death, neurite outgrowth and dendritic formation, vasodila-
tion insensitivity and animal mortality (38). In this study, we 
demonstrate that treatment with FSD-C10, as a new ROCK 
inhibitor, was able to reverse cognitive impairment, possibly 
through decreasing Aβ accumulation and Tau phosphorylation 
in the cortex and hippocampus of APP/PS1 transgenic mice.
A series of studies have demonstrated that ROCK was elevated 
in the brain of AD patients compared to controls (39,40), and 
inhibition of ROCK activity decreased Aβ levels by enhancing 
APP protein degradation (41). Abnormal activation of ROCK 
has also been found in AD experimental models, and may be 
involved in the occurrence and development of diseases (41). 
ROCK activation increased Aβ production, CRMP-2 phos-
phorylation and hindered tubulin assembly, leading to the 
inhibition of synapses (20,42). Inhibition of ROCK reduced the 
production of Aβ (41) and increased the synaptic density and 
length of hippocampal pyramidal neurons (43). Fasudil has 
been proved to protect against nerve degeneration induced by 
Aβ, and to improve spatial memory and learning ability in AD 
Figure 4. FSD-C10 reduces Tau phosphorylation and BACE expression in hippocampus and cortex in APP/PS1 Tg mice. p-Tau and BACE were measured by 
immunohistochemistry and western blot two months after FSD-C10 administration. (A) The numbers of p-Tau and BACE positive cells in hippocampus and 
cortex were measured by immunohistochemistry and (B) their protein expression was measured in brain by western blot. Quantitative results are shown as 
mean ± SEM of 4 mice each group, and one representative of three independent experiments. *P<0.05 and **P<0.01 vs. APP/PS1+NS.
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rats (44). Our present study provides further evidence that inhib-
iting ROCK activity can improve cognitive deficits in APP/PS1 
transgenic mice.
In clinical practice, Fasudil has several limitations, 
including a relatively narrow safety window, poor oral bioavail-
ability, and unsuitability for long-term use. Researchers are 
looking for novel ROCK inhibitors that are more efficient and 
safer, can be taken orally and over a long period of time for the 
treatment of neurodegenerative disorders. We have in previous 
studies found that FSD-C10, as a novel ROCK inhibitor, has 
the same therapeutic effect, but is safer than Fasudil (38). In 
EAE, FSD-C10 ameliorated the clinical severity of disease, 
Figure 5. FSD-C10 induces the expression of synaptophsin, AMPAR-1, AMPAR-2 and PSD-95 protein in hippocampus or cortex in APP/PS1 Tg mice. 
Synaptophsin, AMPAR-1, AMPAR-2 and PSD-95 were measured by immunohistochemistry and western blot two months after FSD-C10 administration. 
(A) The numbers of synaptophsin, AMPAR-1 and AMPAR-2 positive cells in hippocampus or cortex were measured by immunohistochemistry; (B) their 
protein in brain was measured by western blot. Quantitative results are shown as mean ± SEM of 4 mice each group, and one representative of three indepen-
dent experiments. *P<0.05 and **P<0.01 vs. APP/PS1+NS.
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accompanied by improvement in demyelination and the inhi-
bition of inflammatory cells in the CNS of EAE mice, clearly 
showing a therapeutic effect (45).
Glutamate, the major excitatory neurotransmitter in the 
CNS, is involved in synaptic transmission, neuronal growth 
and differentiation, synaptic plasticity and learning and 
memory (46). When a neuron is depolarized, glutamate is 
released into the synaptic cleft where it binds glutamate 
receptors (47). Glutamate receptors, such as NMDA receptor 
and AMPA receptor, are involved in rapid excitatory synaptic 
transmission and the release of neurotransmitters, which 
is closely related with learning and memory (48). In the 
postsynaptic membrane, an AMPAR insert can induce and 
promote learning and memory behavior. Aβ-induced decline 
in AMPAR number and synaptic function through endocy-
tosis is a plausible mechanism for the cognitive impairment 
that occurs in the very early stages of AD (49). Further study 
found that lack of AMPAR can cause dendritic spine reduc-
tion and loss of NMPAR (50), both of which are related to 
cognitive impairment. In our study, increased expression of 
AMPAR, synaptophsin and PSD-95 protein after FSD-C10 
administration could be an important mechanism for the 
improvement in cognitive function in transgenic APP/PS1 
mice. PSD-95 organizes synaptic proteins to mediate the 
functional and structural plasticity of the excitatory 
synapse and to maintain synaptic homeostasis (51). The 
stabilization of a new synaptic protrusion is associated with 
activity-driven PSD proteinaceous network formation. In this 
proteinaceous network, PSD-95 is believed to play a role in 
synapse maturation, given that it is particularly vulnerable 
to the toxic effects of Aβ  (28). Synaptophysin is the major 
integral membrane protein of presynaptic vesicles required 
for vesicle formation and exocytosis (52). Taken together, 
FSD-C10 may maintain the normal function of the synapse, 
Figure 6. FSD-C10 promotes the expression of neurotrophic factors in hippocampus or cortex in APP/PS1 Tg mice. The expression of BDNF and GDNF 
protein was measured by immunohistochemistry and western blot two months after FSD-C10 administration. (A) The numbers of BDNF and GDNF positive 
cells in hippocampus and cortex by immunohistochemistry; and (B) their protein expression in brain by western blot. Quantitative results are shown as 
mean ± SEM of 4 mice each group, and one representative of three independent experiments. *P<0.05 and **P<0.01 vs. APP/PS1+NS.
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possibly through promoting the expression of these synaptic 
related proteins.
Neurotrophic factors play an essential role in the survival of 
neurons affected by degenerative processes (53,54). Increased 
levels of BDNF are associated with improved learning and 
memory, and a reduction in BDNF leads to age-related memory 
deficits (55). The potential of GDNF against age-related 
cognitive deterioration has not been fully explored. It was 
reported that serum GDNF levels were significantly reduced 
in AD patients (56,57), and expression of GDNF transgene in 
astrocytes improved cognitive deficits in aged rats (58). Thus, 
increased BDNF, GDNF, AMPAR, PSD-95, or synaptophysin 
levels may reflect increased synaptic density, activity, and 
vesicles, revealing improved functioning of synapses. Inducing 
expression of these molecules could therefore be a mecha-
nism underlying improved learning and memory abilities of 
the APP/PS1 transgenic mice after FSD-C10 treatment. The 
limitations of this study may include that further mechanisms 
underlying the inhibitory effect on Aβ after blocking ROCK 
activity in AD remain unknown, and the oral effect of this 
reagent in AD mice needs be tested. These questions will be 
further explored in the near future.
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